292 related articles for article (PubMed ID: 27863261)
1. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma.
Jiménez C; Jara-Acevedo M; Corchete LA; Castillo D; Ordóñez GR; Sarasquete ME; Puig N; Martínez-López J; Prieto-Conde MI; García-Álvarez M; Chillón MC; Balanzategui A; Alcoceba M; Oriol A; Rosiñol L; Palomera L; Teruel AI; Lahuerta JJ; Bladé J; Mateos MV; Orfão A; San Miguel JF; González M; Gutiérrez NC; García-Sanz R
J Mol Diagn; 2017 Jan; 19(1):99-106. PubMed ID: 27863261
[TBL] [Abstract][Full Text] [Related]
2. A New Next-Generation Sequencing Strategy for the Simultaneous Analysis of Mutations and Chromosomal Rearrangements at DNA Level in Acute Myeloid Leukemia Patients.
Prieto-Conde MI; Corchete LA; García-Álvarez M; Jiménez C; Medina A; Balanzategui A; Hernández-Ruano M; Maldonado R; Sarasquete ME; Alcoceba M; Puig N; González-Calle V; García-Sanz R; Gutiérrez NC; González-Díaz M; Chillón MC
J Mol Diagn; 2020 Jan; 22(1):60-71. PubMed ID: 31605801
[TBL] [Abstract][Full Text] [Related]
3. Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing.
Ryland GL; Jones K; Chin M; Markham J; Aydogan E; Kankanige Y; Caruso M; Guinto J; Dickinson M; Prince HM; Yong K; Blombery P
J Clin Pathol; 2018 Oct; 71(10):895-899. PubMed ID: 29760015
[TBL] [Abstract][Full Text] [Related]
4. A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma.
Bolli N; Li Y; Sathiaseelan V; Raine K; Jones D; Ganly P; Cocito F; Bignell G; Chapman MA; Sperling AS; Anderson KC; Avet-Loiseau H; Minvielle S; Campbell PJ; Munshi NC
Blood Cancer J; 2016 Sep; 6(9):e467. PubMed ID: 27588520
[TBL] [Abstract][Full Text] [Related]
5. Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing.
Gralewski JH; Post GR; van Rhee F; Yuan Y
Diagn Pathol; 2018 Feb; 13(1):15. PubMed ID: 29463311
[TBL] [Abstract][Full Text] [Related]
6. A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5.
White BS; Lanc I; O'Neal J; Gupta H; Fulton RS; Schmidt H; Fronick C; Belter EA; Fiala M; King J; Ahmann GJ; DeRome M; Mardis ER; Vij R; DiPersio JF; Levy J; Auclair D; Tomasson MH
Blood Cancer J; 2018 Mar; 8(3):35. PubMed ID: 29563506
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P).
Kortüm KM; Langer C; Monge J; Bruins L; Zhu YX; Shi CX; Jedlowski P; Egan JB; Ojha J; Bullinger L; Kull M; Ahmann G; Rasche L; Knop S; Fonseca R; Einsele H; Stewart AK; Braggio E
Ann Hematol; 2015 Jul; 94(7):1205-11. PubMed ID: 25743686
[TBL] [Abstract][Full Text] [Related]
8. Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature.
Lionetti M; Barbieri M; Manzoni M; Fabris S; Bandini C; Todoerti K; Nozza F; Rossi D; Musto P; Baldini L; Neri A
Oncotarget; 2016 Apr; 7(16):21353-61. PubMed ID: 26870891
[TBL] [Abstract][Full Text] [Related]
9. Genomic analysis of multiple myeloma using targeted capture sequencing in the Japanese cohort.
Kanamori T; Sanada M; Ri M; Ueno H; Nishijima D; Yasuda T; Tachita T; Narita T; Kusumoto S; Inagaki A; Ishihara R; Murakami Y; Kobayashi N; Shiozawa Y; Yoshida K; Nakagawa MM; Nannya Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Horibe K; Handa H; Ogawa S; Iida S
Br J Haematol; 2020 Dec; 191(5):755-763. PubMed ID: 32386081
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma.
Yellapantula V; Hultcrantz M; Rustad EH; Wasserman E; Londono D; Cimera R; Ciardiello A; Landau H; Akhlaghi T; Mailankody S; Patel M; Medina-Martinez JS; Arango Ossa JE; Levine MF; Bolli N; Maura F; Dogan A; Papaemmanuil E; Zhang Y; Landgren O
Blood Cancer J; 2019 Dec; 9(12):101. PubMed ID: 31827071
[TBL] [Abstract][Full Text] [Related]
11. Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients.
Kazandjian D; Hill E; Hultcrantz M; Rustad EH; Yellapantula V; Akhlaghi T; Korde N; Mailankody S; Dew A; Papaemmanuil E; Maric I; Kwok M; Landgren O
Blood Cancer J; 2019 Feb; 9(2):15. PubMed ID: 30718460
[TBL] [Abstract][Full Text] [Related]
12. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.
Vij R; Mazumder A; Klinger M; O'Dea D; Paasch J; Martin T; Weng L; Park J; Fiala M; Faham M; Wolf J
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):131-139.e1. PubMed ID: 24629890
[TBL] [Abstract][Full Text] [Related]
13. Genomic profiling of multiple myeloma: New insights and modern technologies.
Hultcrantz M; Yellapantula V; Rustad EH
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101153. PubMed ID: 32139018
[TBL] [Abstract][Full Text] [Related]
14. Assessing genome-wide copy number aberrations and copy-neutral loss-of-heterozygosity as best practice: An evidence-based review from the Cancer Genomics Consortium working group for plasma cell disorders.
Pugh TJ; Fink JM; Lu X; Mathew S; Murata-Collins J; Willem P; Fang M;
Cancer Genet; 2018 Dec; 228-229():184-196. PubMed ID: 30393007
[TBL] [Abstract][Full Text] [Related]
15. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.
Walker BA; Boyle EM; Wardell CP; Murison A; Begum DB; Dahir NM; Proszek PZ; Johnson DC; Kaiser MF; Melchor L; Aronson LI; Scales M; Pawlyn C; Mirabella F; Jones JR; Brioli A; Mikulasova A; Cairns DA; Gregory WM; Quartilho A; Drayson MT; Russell N; Cook G; Jackson GH; Leleu X; Davies FE; Morgan GJ
J Clin Oncol; 2015 Nov; 33(33):3911-20. PubMed ID: 26282654
[TBL] [Abstract][Full Text] [Related]
16. Multiple Myeloma Genomics: A Systematic Review.
Weaver CJ; Tariman JD
Semin Oncol Nurs; 2017 Aug; 33(3):237-253. PubMed ID: 28729121
[TBL] [Abstract][Full Text] [Related]
17. Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease.
Kortüm KM; Langer C; Monge J; Bruins L; Egan JB; Zhu YX; Shi CX; Jedlowski P; Schmidt J; Ojha J; Bullinger L; Liebisch P; Kull M; Champion MD; Van Wier S; Ahmann G; Rasche L; Knop S; Fonseca R; Einsele H; Stewart AK; Braggio E
Br J Haematol; 2015 Feb; 168(4):507-10. PubMed ID: 25302557
[TBL] [Abstract][Full Text] [Related]
18. Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma.
Hultcrantz M; Rustad EH; Yellapantula V; Jacob A; Akhlaghi T; Korde N; Mailankody S; Lesokhin AM; Hassoun H; Smith EL; Lahoud OB; Landau HJ; Shah GL; Scordo M; Chung DJ; Giralt S; Papaemmanuil E; Landgren O
Clin Cancer Res; 2022 May; 28(10):2160-2166. PubMed ID: 35553646
[TBL] [Abstract][Full Text] [Related]
19. Genomic Aberrations in Multiple Myeloma.
Manier S; Salem K; Glavey SV; Roccaro AM; Ghobrial IM
Cancer Treat Res; 2016; 169():23-34. PubMed ID: 27696256
[TBL] [Abstract][Full Text] [Related]
20. The combination of WGS and RNA-Seq is superior to conventional diagnostic tests in multiple myeloma: Ready for prime time?
Höllein A; Twardziok SO; Walter W; Hutter S; Baer C; Hernandez-Sanchez JM; Meggendorfer M; Haferlach T; Kern W; Haferlach C
Cancer Genet; 2020 Apr; 242():15-24. PubMed ID: 31980417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]